Clinical trial · Observational
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
Construction of Molecular Diagnostic Marker Models for Pancreatic Cystic Tumors Based on CfDNA Methylation Sequencing and Proteomic Analysis of Pancreatic Cystic Fluid Samples
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. Participants will Provide post-operative cyst fluid specimens.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DNA Methylation | — | UNRESOLVED | — |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Proteome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cfDNA methylation sequencing and proteome analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Mucinous tumour group
- interventionNames
- Diagnostic Test: cfDNA methylation sequencing and proteome analysis
- label
- Non-mucinous tumour group
- interventionNames
- Diagnostic Test: cfDNA methylation sequencing and proteome analysis
Primary outcomes (1)
- measure
- Types and concentrations of cfDNA and proteins contained in the vesicular fluid
- timeFrame
- 2023-11-31
- description
- Identification of protein and circulating gene methylation species in cyst fluid and quantification of their concentrations using mass spectrometry. Characterize cfDNA methylation and proteomics of cyst fluid in patients with pancreatic cystic neoplasm (PCN).
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects are ≥ 18 years old, regardless of gender; * Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor; * Subjects voluntarily accepted radical resection of pancreatic cystic tumors; * Subjects or family members voluntarily sign the informed consent form for clinical research. Exclusion Criteria: * The excised sample does not contain cystic components, or the cystic fluid cannot be collected; * Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation; * Receive antibiotic treatment within 1 week before operation; * Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor; * The subjects or their families refused to sign the informed consent form for clinical research.
References
Publications (0)
Data not yet available